KUR 112

Drug Profile

KUR 112

Alternative Names: I-040302; TGplPTH1-34

Latest Information Update: 21 Oct 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Kuros Biosurgery
  • Developer Kuros Biosciences
  • Class Blood proteins; Peptide hormones; Recombinant fusion proteins
  • Mechanism of Action Osteogenesis stimulants; Parathyroid hormone receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Bone cysts
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Bone cysts

Most Recent Events

  • 20 Oct 2016 KUR 112 receives Rare Paediatric Disease designation for Solitary bone cysts in USA
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Bone-cysts in Switzerland (Intralesional, Injection)
  • 06 Jan 2009 Phase-I clinical trials in Bone cysts in Switzerland (Intralesional)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top